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Abstract. colonic cancer has become a main reason of 
mortality associated with cancer; however, left and right-sided 
colonic cancer have diverse outcomes in terms of epide-
miological, histological, clinical parameters and prognosis. 
We aimed to examine the discrepancies between these two 
types of colon cancers to identify potential therapeutic 
targets. In the present study, three gene expression profiles 
(GSe44076, GSe31595, GSe26906) from Gene expression 
omnibus (Geo) database were downloaded and further 
analyzed. a PPi (protein-protein interaction) network of the 
differentially-expressed genes (deGs) of GSe44076 between 
tumor and normal was established with the Search Tool for the 
retrieval of interacting Genes database. Then, the deGs of 
these two colon cancers (left, right) samples were identified. 
Subsequently, the intersection of deGs of left and right-sided 
colon cancer samples obtained from three databases, and 
deGs of tumor and normal samples were analyzed. collagen 
type Xi α1 chain (col11a1), Twist family bHlH transcrip-
tion factor 1 (TWiST1), insulin-like 5 and chromogranin a 
were upregulated proteins, while 3β-hydroxysteroid dehydro-
genase was downregulated protein in right colon cancer than 
in left-sided tumor samples. Through further experimental 
verification, we revealed that COL11A1 and TWIST1 were 
significantly upregulated at the mrna and protein levels 
within right-sided colon cancer compared with in left-sided 
colon cancer samples (P<0.05), consistent with bioinfor-
matical analysis. Furthermore, a positive correlation between 
col11a1 and TWiST1 protein expression was observed 
(P<0.0276). collectively, our data showed that col11a1 and 
TWiST1 may be potential prognostic indicators and molecular 
targets for the treatment of right-sided colon cancer.
Introduction
colonic cancer has become the most common cancer, as well 
as a general cause of human mortality from cancer. Mortality 
rates from colonic cancer are predicted to increase substan-
tially in costa rica, australia, the united States, ireland 
and canada, with the mortality rate expected to rise by 60% 
until 2035 (1). It was also identified that left and right‑sided 
colon cancer differs significantly with reference to histo-
logical, epidemiological and clinical parameters (2,3). in 
addition, patients suffering from right-sided colonic cancer 
usually have worse prognosis than those with the other 
types of cancer (4). These variations may be due to genetic 
differences that induce distinct carcinogenic and biological 
behaviors. The impact of these findings on screening and 
treatment remains to be elucidated (2). Thus, it is crucial to 
further investigate the disparity between two types of colon 
cancers, which may be beneficial in suppressing the spread 
of primary cancer.
in order to further identify the variable genetic expression 
of the two colon cancers, the GSe44076 (5), GSe31595 (6) and 
GSe26906 (7) datasets were downloaded from the database 
of Gene expression omnibus (Geo). We then analyzed the 
data to screen differential expression of genes (deGs) and 
construct a protein-protein interaction (PPi) network. Through 
database analysis, we found several genes that were signifi-
cantly upregulated or downregulated, respectively, in left and 
right-sided colonic cancer. 
Several lines of evidence indicated that col11a1 was 
upregulated in various cancers, including colorectal (8-10), 
pancreatic (11), non-small cell lung (12), breast (13), ovarian (14), 
and head region and neck squamous cell cancer (15), suggesting 
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an oncogenic role for col11a1. regarding the formation and 
progression of tumors, COL11A1 was confirmed to facilitate 
the progression of ovarian, and head and neck squamous cell 
carcinoma (14-16). it was also reported as a possible biomarker 
of colon cancer (12,17). 
The expression of TWiST1, a key factor in the conver-
sion of epithelial-mesenchymal transition (eMT), is closely 
associated with the high probability of tumorigenesis, chemo-
therapeutic resistance, poor prognosis and metastasis (18-20). 
Furthermore, TWiST1 was be found to be overexpressed in 
various malignant tumors, such as cancer of the thyroid (21), 
esophagus (22), breast (23), lung (24), stomach (25), 
pancreas (26), hepatocytes (27), colon (28) and cervix (29). 
Thus, the expression of TWiST1 is often used as a potential 
target for cancer treatment (27,30-32).
Through database analysis, we determined col11a1, 
TWiST1, insulin-like 5 (inSl5) and chromogranin a (cHGa) 
to be hub proteins for upregulation, and 3β-hydroxysteroid 
dehydrogenase (HSd3B2) was a hub protein for down-
regulation. To further verify the importance of these genes in 
left- and right-sided colon cancer, we selected and determined 
the expression levels of col11a1 and TWiST1 in various 
tissue samples obtained from our department. Through the 
combination of database and experimental analyses, the 
present study is the first to identify genetic dissimilarities 
between these two colon cancer types to the best of our knowl-
edge. Our findings also revealed that the mRNA and protein 
expression levels of col11a1 and TWiST1 were upregulated 
in right-sided colonic cancer than in left-sided tumor samples. 
This suggested that col11a1 and TWiST1 may be potential 
prognostic markers and/or molecular targets for the treatment 
of right-sided colon cancer.
Materials and methods
Ethics statement. The present study was approved by the 
ethics committee of Xiamen university. in total, 17 left-sided 
colonic cancer and 13 right-sided colonic cancer samples were 
collected from the Zhongshan Hospital of Xiamen university 
between august 2014 and august 2015 (the patients and 
samples are characteristics in Table i). This research was 
conducted in accordance with the declaration of Helsinki (33), 
the international ethics Standards for Human Biomedical 
research (34) and the relevant provisions of the national 
natural Science Foundation of china, jointly supported by the 
World Health organization and the international council of 
Medical Science organizations (35).
Gene expression profile data. We downloaded and used three 
datasets from the Geo database and the data of patients 
enrolled in this study. The inclusion criteria were set as 
follows: i) Patients with clinical information, including the site 
of resection or biopsy; and ii) patients with complete cancer 
data and normal data.
GSe44076 is a dataset containing 246 samples provided 
by Solé et al (5), utilizing affymetrix Human Genome u219 
array platform. The dataset comprised 66 colon resected 
left-sided colonic cancer samples and 38 right-sided samples 
from colonic carcinoma tissues, as well as 98 normal samples 
for colonic tissues.
The GSe31595 dataset constituted 37 samples provided 
by Thorsteinsson et al (6), utilizing the affymetrix Human 
Genome u133 Plus 2.0 array platform. This dataset comprised 
14 colon resected left-sided colonic cancer samples and 23 
right-sided samples from colonic carcinoma tissues.
The GSe26906 dataset contained 90 samples provided 
by Birnbaum et al (7), utilizing affymetrix Human Genome 
u219 array platform. The dataset comprised 65 colon resected 
left-sided colonic cancer samples and 25 right-sided samples 
from colonic carcinoma tissues.
Data pre‑processing and DEG analysis. We used the affy 
package (36) to preprocess the three separate datasets, 
correcting their background and transforming them from 
probe level into gene symbol. robust multiarray average was 
used to normalize the values of probe level intensity and the 
signal estimates of generated probe set. Subsequently, the 
deGs between left and right-sided colonic cancer of three 
separate datasets were conducted by utilizing the limma 
package (37) in r. We calculated the fold-change (Fc) of 
relative genetic expression, and the threshold criteria of 
DEG selection were P<0.05 and |log2FC|≥1. Subsequently, 
on the basis of limma package in r, we selected deGs 
between colon cancer and normal samples with the dataset of 
GSe44076 (37). We also calculated the Fc in relative gene 
expression. This threshold criteria used for deG selection 
were P<0.05, |log2FC|≥2.
PPI network construction of the DEGs between colonic 
cancers and normal tissue samples. The potential interac-
tions among the deGs between colonic cancers and normal 
tissue samples in the GSe44076 dataset was predicted by the 
Search Tool for the retrieval of interacting Genes (STrinG) 
database (version 10) (38,39). The proteins from database were 
entered in STrinG. With the criterion of a combined score 
of >0.4, and as visualized with cytoscape (version 3.2.1), only 
interactions which contained at least one deG were selected 
to establish the PPi network (40).
Identification of the hub gene between left and right‑sided 
colonic cancer. We obtained the intersection of total deGs of 
left-sided compared with right-sided colonic cancer in three 
separate datasets, and the deGs of GSe44076 between colon 
cancers and normal tissues with the criterion of a combined 
score of >0.4. The deGs contained in the intersection were 
identified as the hub gene.
Prognoscan database analysis and literature review. 
We utilized the PrognoScan database (http://www.abren.
net/PrognoScan/) to analyze potential associations between 
deGs and survival in colon cancer using Kaplan-Meier 
analysis (41). Furthermore, the patients were compared on the 
basis of high and low expression to analyze survival according 
to the PrognoScan database. in order to select oncogenes for 
further analysis, a literature search of PubMed was performed 
for each gene using the term ‘Gene naMe]’, ‘cancer’.
Tumors. in the present study, mrna droplet digital™-Pcr 
was run on the pane of 17 fresh-frozen left-sided colonic 
cancer tissues and 13 right-sided samples collected at 
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the Zhongshan Hospital of Xiamen university between 
2014 and 2015 (Table I). All samples were frozen at ‑80˚C 
immediately after collection by surgeons who directly took 
part in the study and removed the surgical specimens. The 
mean age of the 17 patients was 64.82 years (ranging from 
43-83 years-old) and the maximum tumor diameter ranged 
from 2.7-12 cm (mean, 5.476 cm) in left sided colon cancer. 
The mean age of the 13 patients was 61.15 years (ranging 
from 39-82 years-old) and the maximum tumor diameter 
ranged from 2-10 cm (mean, 5.362 cm) in right sided colon 
cancer. There were no significant differences between the 
two groups in age (P=0.4281) and maximum tumor diameter 
(P=0.8824). 
Cell culture and transfection. The colon cancer HcT116 cell 
line was purchased from the institute of cell Biology and 
cultured in RPMI‑1640 (Gibco; Thermo Fisher Scientific, 
inc.) supplemented with 10% FBS (excell Bio, Shanghai, 
china), 100 u/ml penicillin and 100 µg/ml streptomycin 
at 37˚C in a humidified incubator containing 5% CO2. in 
total, 5 µg Flag-TWiST1 or col11a1 plasmids (Public 
Protein/Plasmid library) were transfected into HcT116 
cells; after 36 h, the cells were collected. TWiST1 or 
col11a1 expression was analyzed using a Flag-antibody. 
The expression levels of e-cadherin and n-cadherin or 
inhibitor of nF-κB (iKKβ) were determined using reverse 
transcription-quantitative (rT-q) Pcr, and the expression 
levels were normalized to GaPdH. The results are presented 
as the mean ± Sd of three independent experiments. Plasmid 
dna transfections were performed with Turbofect reagent 
(Invitrogen; Thermo Fisher Scientific, Inc.), according to the 
manufacturer's instructions.
Western blotting. The colon cancer samples were lysed 
with cell lysis buffer 20 mM Tris-Hcl (pH 7.5), 20 mM 
β-glycerophosphate, 150 mM nacl, 1 mM sodium orthovana-
date, 1 mM PMSF, 10 mM naF, 10 µg/ml leupeptin, 2 µg/ml 
aprotinin,1% Triton X-100 and 1 mM edTa]. Protein concen-
tration was determined using the bicinchoninic acid method 
and 80 µg of total protein was used for western blotting. 
Protein lysates were separated using 12% SdS-PaGe and 
transferred to nitrocellulose membranes. The membranes 
were blocked for 1 h in 5% BSa and incubated with primary 
antibodies overnight at 4˚c, washed, and incubated with 
secondary antibodies (1:5,000) for 1 h. The membranes were 
then washed and the protein bands were visualized using the 
immobilon Western chemiluminescent HrP Substrate Kit 
(eMd Millipore).
Western blotting was performed with the following 
primary antibodies: actin monoclonal antibody (1:5,000; cat. 
no. a5441; Sigma-aldrich; Merck KGaa), Twist1 (1:1,000; 
cat. no. 46702; cell Signaling Technology, inc.) and col11a1 
(1:1,000; cat. no. 42818; cell Signaling Technology, inc.). The 
horseradish peroxidase-conjugated secondary goat anti-rabbit 
and goat anti-mouse (1:5,000; cat. nos. 31466 and a16078; 
Thermo Fisher Scientific, Inc.). densitometry was performed 
using Quantity one software (Bio-rad laboratories, inc.).
RNA isolation, reverse transcription‑quantitative PCR 
(RT‑qPCR). in the present study, total rna was isolated using 
the rna Simple Total rna Kit (Biotek, inc.), according 
to the manufacturer's instructions, and first-strand cdna 
was obtained by utilizing First-strand cdna Synthesis Kit 
(Biotek, inc.). The rT reaction was performed at 42˚c for 
60 min and 85˚c for 5 min, the cdna was stored at -20˚c. 
We amplified cDNA samples via qPCR and the SYBR Green 
real-Time Pcr Master Mix (Toyobo life Science) utilizing 
an aBi 7500 real-Time Pcr System (applied Biosystems; 
Thermo Fisher Scientific, Inc.) with the following primers: 
GaPdH forward, 5'-TcT ccT cTG acT Tca aca GcG a-3' 
and GaPdH reverse, 5'-GTc cac cac ccT GTT GcT GT-3'; 
TWiST1 forward, 5'-GGc caG GTa caT cGa cTT cc-3', 
TWiST1 reverse, 5'-Tcc aGa ccG aGa aGG cGT aG-3'; 
col11a1 forward, 5'-caa cTc aGc caT ccT Gac TT-3', 
col11a1 reverse, 5'-GTc Tca cca cca GaT GTG aa-3'. 
The thermocycling conditions for the qPcr were as follows: 
15 min at 95˚c, followed by 10 cycles of 30 sec at 94˚c, 90 sec 
at 72˚c; and 20 cycle of 30 sec at 94˚c, 90 sec at 58˚c and 
60 sec at 72˚C, with a final incubation for 60 min at 72˚c.
Statistical analysis. data are presented the mean ± Sd of at 
lowest three individual experiments. all statistical tests were 
performed using Graphpad Prism 6.0 (GraphPad Software, 
inc.). one-way anoVa followed by a Bonferroni's post-test 
for manifold comparisons, and pair-wise comparisons with 
Student's test (two-tailed) were conducted. The correlation 
analyses were proceeded with Pearson's test. P<0.05 was 
considered to indicate a statistically significant difference. 
Confirmed by continually changing the cut‑off values in 
the analysis of all our results, receiver operating curves (roc) 
curves were established by all potential specificity/sensitivity 
pairs with an particular detection method (42). in our study, 
roc curves were used to identify the hub genes that would be 
Table Ⅰ. Clinicopathological characteristics in colon cancer 
samples.
 Tumor location
clinicopathological ------------------------------
parameters left right P-value
age, years   0.269
  ≥50 10 5 
  <50 7 8 
Sex   0.004
  Male 13 3 
  Female 4 10 
TnM stage   0.633
  Tis +i 2 0 
  ii 10 8 
  iii 4 4 
  iV 1 1 
Histology grade   0.432
  Well + moderate 12 10 
  Poor 3 3 
Mucinous adenocarcinoma 2 0
TnM, tumor-node-metastasis; Tis, carcinoma in situ.
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highly predictive of the tissue samples and could distinguish 
between left and right-sided colon cancer tissues.
Functional enrichment analysis. To investigate the func-
tions that may be changed by the DEGs identified, functional 
Gene ontology (Go) enrichment analysis was performed 
using database for annotation, Visualization, and integrated 
discovery (version 6.8; https://david.ncifcrf.gov/) (43) to deter-
mine the biological functions of these deGs between tumor 
and normal tissues. an enriched gene count >2 and cut-off 
criteria were selected based on P<0.05 in our study. 
Results
Screening of DEGs. To further identify the differential gene 
expression between these two types colonic cancers, we selected 
and downloaded the GSe44076, GSe31595 and GSe26906 
gene expression datasets from the Geo database for deG 
screening (Fig. 1). The GSe44076 dataset, amounting to 48 
deGs, revealed 20 upregulated and 28 downregulated deGs. 
The GSe31595 dataset, amounting to 46 deGs, contained 21 
upregulated and 25 downregulated deGs. The GSe26906 
dataset, amounting to 34 deGs, revealed 23 upregulated and 
11 downregulated deGs. additionally, these deGs of tumor 
and normal tissues were employed for further analysis using 
the GSe44076 dataset (Table ii).
PPI network. a PPi network with these deGs between tumor 
and normal tissues was constructed from pre-processing of the 
GSe44076 dataset, via analysis with STrinG and cytoscape 
software. Proteins and related interactions were symbolized 
by nodes and lines respectively in the PPi network, which 
consisted of GSe44076, including 228 proteins and 683 inter-
actions (Fig. 2). in the PPi network, the hub proteins should 
be the nodes with an average connective degree ≥5. From 
PPi network analysis, we could identify network of various 
proteins in colon cancer. 
Analysis the association between DEGs and survival. 
Subsequently, we obtained the intersection of deGs between 
left and right-sided colonic cancers obtained from the three 
aforementioned databases and deGs of tumor and normal 
samples (Fig. 3a). col11a1, TWiST1, inSl5 and cHGa were 
determined to be upregulated proteins, while HSd3B2 was 
downregulated protein in right-sided colonic cancer samples 
than left-sided tissues. among them, col11a1, TWiST1 and 
HSD3B2 were in accordance with the DEG profiles of tumor 
and normal tissue. We plotted roc curves for these proteins. 
The closer to upper-left corner the roc curves are, the more 
accurate the test is. The genes we screened exhibited a typical 
trend (Fig. 3B). in addition, through Kaplan-Meier analysis, 
upregulated col11a1 and TWiST1 was associated with poor 
survival rates in colon cancer. By contrast, the downregula-
tion of HSd3B2 exhibited generally poor survival rates in 
colon cancer. inSl5 and cHGa were not associated with a 
statistically significant difference in survival rates (Fig. 3c). 
We performed a literature search of PubMed for each gene 
using the terms ‘Gene naMe]’, ‘cancer’. Of the five genes, 
according to a previous study col11a1, and TWiST1 had 
been described as being candidate oncogene (44); therefore, 
in subsequent analyses, we selected two of them (col11a1 
and TWIST1) for the further verification.
Verification of the DEGs (COL11A1 and TWIST1) between 
left and right‑sided colonic cancer with western blotting 
analysis and RT‑qPCR. in order to estimate the levels of 
col11a1 and TWiST1 expression that are implicated in these 
two sorts of colon cancer, we performed rT-qPcr analysis 
Figure 1. Screening of differentially-expressed genes. The GSe44076 gene expression datasets were downloaded from the Gene expression omnibus database 
and the upregulated DEGs and downregulated DEGs between tumor and normal tissues were identified. DEGs, differentially‑expressed genes.
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of 17 fresh frozen left-sided colonic cancer samples and 13 
right-sided ones obtained from our department (Table iii). it 
was shown that the levels of col11a1 and TWiST1 expres-
sion in cell samples of right-sided colonic cancer samples 
were significantly higher than that in the left side samples 
(Tables iii and iV, Fig. 4a and B). The protein expression 
levels of col11a1 and TWiST1 in the two types of cancer 
tissues were detected via western blotting analysis. in accor-
dance with the rT-qPcr results, significantly increased 
levels of col11a1 and TWiST1 expression were observed 
in right-sided colon cancer tissues than in left-sided tumor 
samples (Tables iii and iV, Fig. 5a-c). We also analyzed 
the correlation between the expression of col11a1 and 
TWiST1 proteins in colonic cancer samples. The expression of 
col11a1 and TWiST1 proteins exhibited a positive correla-
tion (Figs. 4c and 5d), indicating that the two proteins could 
serve key roles during the formation and progression of these 
two types colonic cancers.
Functional enrichment analysis. The Go analysis suggested 
that col11a1 was involved in ‘proteinaceous extracellular 
matrix’, ‘collagen trimer’ and ‘chondrocyte development’, 
and TWiST1 was involved in ‘osteoblast differentiation’, 
transcription factor activity of rna polymerase ii, ‘positive 
regulation of transcription from rna polymerase ii promoter’, 
‘sequence‑specific DNA binding’ and ‘nucleus’ (Table V).
Discussion
In 1990, Bufill was the first to report that distinct biological 
pathways may be associated with left and right colonic carci-
noma (45). Since then, many studies have revealed significant 
Table II. DEGs were identified from three profile datasets, including up‑regulated genes and down‑regulated genes in which 
the colon cancer tissues compared with normal colon tissues and right-sided colon cancer tissues compared to left-sided colon 
cancer. 
deGs upregulated genes downregulated genes
GSe44076 tumor il8, MYc, MMP9, ccnB1, aGT, BuB1,  cXcl12, SST, nPY, PYY, ccl19, GcG, 
and normal cenPa, cXcl1, TPX2, ceP55, uBe2c, adra2a, inSl5, cd36, ca2, cHGa, FaBP4, 
 nuF2, cXcl11, cXcl5, GnG4, TiMP1, ccl13, HSd3B2, ViP, KlF4, ccl23, PcSK2, 
 SPP1, MMP3, Mnd1, cXcl2, TriP13, Pde6a, FaBP1, Muc2, Pde9a, HPGd, oaSl, 
 MMP7, aTad2, MMP1, cXcl3, col1a1, cTSG, rerGl, SGK1, aKr1c1, cFd, Slc4a4,
 anln, ercc6l, cenPH, SKa3, dScc1, deS, MMP28, HSd17B2, darc, PcK1, 
 SPc25, SoX9, lGr5, cdca7, cKaP2, uGT2B15, uGT2B17, adH1B, MYH11, PTGdr
 BMP7, rnaSeH2a, FoXa2, FaM54a,
 FcGr3a, MMP10, diaPH3, col11a1,
 TWiST1, eTV4, lcn2, MYBl2, 
 SulT2B1, coMP, col10a1, FaBP6, 
 MTHFd1l, orc6l, MSX2, FaP
GSe44076 right and left TTPa, TriM54, PnliPrP2, elaVl2,  MB, HoXc6, HoXB6, arX, aiM2, Slc28a3, 
 G0S2, rBP2, MSln, ereG, ZnF43, B3GnT6, l1Td1, dMrTa2, GaBrP, GBa3, 
 Tnnc1, Prac, odaM, QPrT, PcP4, arT3, cldn2, FoXa1, cYP4X1, KrT6B, ca9, 
 col9a3, lY6G6d, BeX2, Slc26a3, HePacaM2, FoXd1, HoXB8, MS4a8B, 
 Gal, cKMT2 c4BPa, dMBT1, MT1H, Muc1, ido1, KlK1, 
  PiGr
GSe31595 right and left FGd1, Prac1, c11orf70, HS3ST3a1, il10, uSP30-aS1, Slc51a, Har1a, crTaM, 
 PKia, Pi3, inSl5, HoXB13, PHacTr3, nKG7, nPY6r, nr1H4, TreH, BlnK, MeP1B, 
 aSB9, SYne4, rln2, FlJ41455, TWiST1, GdPd3, PiTX2, cYP2c18, aiM2, PP7080, 
 cKMT2, Slc35d3, ccdc113, col11a1, cd69, GBa3, GraMd1c, ccl8, HSd3B2, 
 PPBP, ePYc, cPe ccl5, HMGcS2, rarreS3, Slc20a1
GSe26906 right and left Prac1, cldn5, SerPine2, PcdH19,  Pla2G3, riBc2, caPn6, PiWil1, Slc28a3, 
 cHGa, PrelP, SerPina6, Pla1a, GMPr, TMeM171, reG3a, l1Td1, FoXd1, 
 Scnn1B, STMn2, MaP7d2, cHrdl1, cldn2
 Muc12, PcP4, HSd17B6, Mn1,
 arMcX1, cHrdl2, cldn10, ccl11,
 aoc3, clc, BeX2
upregulated genes, represented genes that were upregulated in right-sided colon cancer tissues than in left-sided colon cancer tissues, while 
downregulated genes represented those that were downregulated in right-sided colon cancer tissues than in left-sided colon cancer. deGs, 
differentially expressed genes.
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differences in epidemiological, clinical and histological param-
eters between the two regions of colonic cancers (2-4,46). 
irrespective of age and gender, synchronous/metachronous, the 
level of BraF, microsatellite instability (MSi) and consensus 
molecular subtype (cMS), the location of a primary tumor is 
considered as an important individual prognostic factor for 
colonic cancer (47). Patients with left-sided colonic cancer 
usually have better prognoses than those with right-sided 
colonic cancer (4). Furthermore, there are varying responses 
in palliative chemotherapy, as well as cetuximab and beva-
cizumab owing to tumor location (47-50). Primary left-sided 
colon cancer patients may benefit from the chemotherapy with 
additional cetuximab in both first and second‑line treatments 
for metastatic colorectal cancer (49). it has been reported 
by Venook et al (47) that in treating patients with right-side 
colonic cancer, bevacizumab was more effective than 
Figure 2. PPi network. a PPi network was constructed for the differentially-expressed genes of tumor and normal with pre-processing of the GSe44076 
dataset. PPi, protein-protein interaction. Genes that were upregulated are shown in red and genes that were downregulated are shown in green.
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Figure 3. Analysis of the association between DEGs and survival. (A) Identification of aberrantly differentially expressed genes in gene expression datasets 
(GSe44076, GSe31595 and GSe26906) obtained between left-sided colon cancer and right-sided colon cancer, and gene expression datasets (GSe44076) 
obtained between colon cancer and normal tissues. (B) receiver operating curves for intersection of deGs between left and right-sided colonic cancers 
obtained from the aforementioned datasets and DEGs of tumor and normal samples. (C) Five‑year overall survival. Kaplan‑Meier curves stratified by the 
indicated mrna levels and analyzed by a log-rank test. PrognoScan database was used to analyze the potential correlation between deGs and survival in 
colon cancer. auc, area under the curve; cHGa, chromogranin a; col11a1, collagen type Xi α1 chain; deGs, differentially-expressed genes; HSd3B2, 
3β-hydroxysteroid dehydrogenase; inSl5, insulin-like 5; TWiST1, Twist family bHlH transcription factor 1.
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Table iii. clinicopathological characteristics and col11a1 
mrna expression in colon cancer samples.
  col11a1
clinicopathological no. of expression
parameters cases (2-Δcq, mean) P-value
Tumor location   
  left 17 1.1993 <0.0001
  right 13 2.7947 
TnM stage   
  Tis + i 2 1.1530 0.7026
  ii 18 1.9950 
  iii 8 1.9223 
  iV 2 1.5617 
Histology grade   
  Well + moderate 22 1.8974 0.4455
  Poor 6 2.1369 
Mucinous adenocarcinoma 2 1.0769
col11a1, collagen type Xi α1 chain; TnM, tumor-node-metastasis.
Table Ⅳ. Clinicopathological characteristics and TWIST1 
mrna expression in colon cancer samples.
  TWiST1
clinicopathological no. of expression
parameters cases (2-Δcq, mean) P-value
Tumor location   <0.0001
  left 17 1.1546 
  right 13 2.3867 
TnM stage   0.7767
  Tis + i 2 1.2984 
  ii 18 1.7548 
  iii 8 1.7536 
  iV 2 1.2214 
Histology grade   0.3601
  Well + moderate 22 1.6988 
  Poor 6 1.9118 
Mucinous adenocarcinoma 2 0.9055
TnM, tumor-node-metastasis; TWiST1, Twist family bHlH tran-
scription factor 1.
Figure 4. mrna expression of col11a1 and TWiST1 in colon cancer clinical samples. (a) reverse transcription-quantitative polymerase chain reaction 
assay. The mrna expression levels of col11a1 and TWiST1 in 30 clinical samples were examined by qPcr assay. (B) The statistical data from col11a1 
and TWiST1 mrna levels in various colon cancer clinical samples. col11a1 and TWiST1 were upregulated in right-sided tumors than left-sided tumors. 
(c) Positive correlation between the expression of col11a1 and the expression of TWiST1 mrna in two different colon cancer clinical samples. results are 
representative of three independent experiments, and the error bars represent the standard deviation. col11a1, collagen type Xi α1 chain; TWiST1, Twist 
family bHlH transcription factor 1.
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cetuximab. increasing evidence manifested that molecular 
profiles of cancers may also differ across these sites (51‑54). 
The incidence rate of cpG island methylator phenotype-high, 
BraF mutation, and MSi-high in colorectal cancer increased 
gradually along the bowel from the rectum to the ascending 
colon (54,55). loree et al (56) found that, based on comparing 
the cMS level of an isolated cohort of >600 patients, the 
sigmoid-rectal region appeared to differ from the other sites, 
while the transverse colon differs from other right-sided loca-
tions. Several studies revealed that distal colon cancer has no 
significant differences compared with rectal cancer with refer-
ence to disease-free survival, somatic alterations and overall 
survival (57,58). Thus, it is crucial to investigate the molecular 
variances between two types colonic cancers.
We first reported the differential expression of COL11A1 
and TWiST1 between left and right-sided colonic cancers. We 
observed that col11a1 and TWiST1 mrna were upregu-
lated in right-sided colon cancer tissues than in left-sided 
tissues based on rT-qPcr analysis, which was in accordance 
with our results of bioinformatical analyses.
col11a1 and TWiST1 mrna expression was positively 
related to tumor location. The results support the notion that 
upregulated col11a1 and TWiST1 in right-sided colonic 
cancer may have notable impact on the invasiveness and worse 
prognosis of the right-sided colonic cancer.
Furthermore, it has been known that cancer cells have 
interactions with their surrounding stroma, which was 
associated with the mechanism of tumor cell invasion (59). 
There are two chains of type Xi collagen involved and one 
of them is a smaller fibrous collagen and encoded exactly 
by col11a1 gene (60). additionally, the extracellular 
matrix (ecM) has been considered to be important in 
tumor behavior, and forms the interstitial matrix conducive 
to regulating and integrating cell behavior (61-63). Thus, 
collagens, as major components of ecM, are related to regu-
lation of several important biological processes, including 
cell proliferation, differentiation and migration (64-66). 
in addition, the development of the col11a1 mutations 
was linked with Marshall syndrome and type ii Stickler 
syndrome (67,68). Based on our results, col11a1 is mainly 
enriched in proteinaceous extracellular matrix, collagen 
trimer and chondrocyte development; col11a1 was also 
the predominant node in the PPi network in our study. 
Proteinaceous extracellular matrix-related genes that could 
increase the aggression and change the metastatic properties 
of cells in vivo colon cancer contribute to poor prognosis in 
cancer patients (69). The strong overexpression of col11a1 
has been discovered in various studies for examining diver-
sities between tumor and normal tissues, and linked to the 
metastasis of tumor and poor prognosis (14). a previous 
study reported that the expression of col11a1 of colon 
tumors is related to anaphase-promoting complex/β-catenin 
path of colon cancer metastasis (11). We will continue to 
investigate the mechanism of col11a1 in the two sides of 
colon cancer in future work.
according to the results of the Go and PPi analyses, 
TWiST1 which was enriched in ‘osteoblast differentiation’, 
transcription factor activity of rna polymerase ii, ‘positive 
regulation of transcription from rna polymerase ii 
promoter’, ‘sequence‑specific DNA binding’ and ‘nucleus’, 
was also the predominant node in the PPi network. 
increasing evidence has indicated that cancer cells charac-
terized as cancer stem cells (cSc) or eMT have a strong 
potential to promote the progression, aggression, metastasis 
Table Ⅴ. Functional enrichment analysis for differentially‑expressed genes between tumor and normal contained TWIST1 or 
col11a1 based on Go.
category Term description P-value Genes
GoTerM_cc_direcT Go:0005578 Proteinaceous extracellular 0.0022724 MMP9, coMP, col11a1, MMP1, 
  matrix  col10a1
GoTerM_BP_direcT Go:0001649 osteoblast differentiation 0.0028232 MSX2, col1a1, TWiST1, SPP1
GoTerM_BP_direcT Go:0045944 Positive regulation of 0.0096635 cKaP2, FoXa2, aTad2, BMP7, 
  transcription from rna  MYc, eTV4, TWiST1
  polymerase ii promoter
GoTerM_MF_direcT Go:0000981 rna polymerase ii 0.0108839 FoXa2, MYBl2, eTV4, TWiST1
  transcription factor activity,
  sequence‑specific DNA
  binding
GoTerM_cc_direcT Go:0005581 collagen trimer 0.0135131 col1a1, col11a1, col10a1
GoTerM_BP_direcT Go:0002063 chondrocyte development 0.04367 MSX2, col11a1
GoTerM_cc_direcT Go:0005634 nucleus 0.0498886 FoXa2, nuF2, TPX2, Mnd1,
    aTad2, uBe2c, MYBl2, cenPH, 
    MSX2, SPc25, cdca7, cenPa, 
    MYc, eTV4, TWiST1
BP, biological process; cc, cellular component; col11a1, collagen type Xi α1 chain; Go, Gene ontology; MF, molecular function; 
TWiST1, Twist family bHlH transcription factor 1.
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and chemoresistance of cancer (70-73). it has been shown 
that the eMT program is associated with the self-renewal 
ability of cells and may efficiently induce tumors (74,75). 
it is the essential helix-loop-helix transcription factors 
(such as TWiST1) that crucial for eMT and cSc; one of 
these factors (71) suppresses the expression of e-cadherin 
and promotes eMT during the progression of tumors (76). 
Specifically, in the promoter of e-cadherin, TWiST1 
combines with e-box elements, suppresses the transcription 
of the cell-cell adhesion molecule expression and promotes 
eMT, contributing to metastasis during the progression 
of tumors (77). it has been known that TWiST1 has wide 
expression in many human cancers, including colorectal 
cancer (31), and its strong expression has been linked to poor 
prognosis and chemotherapeutic resistance (27,30-32,78). 
in colorectal cancer patients, TWiST1 expression has been 
Figure 5. Protein expression of col11a1 and TWiST1 in colon cancer clinical samples. (a) Western blotting for the expression of col11a1 and TWiST1 
in colon cancer tissues. (B) densitometry analysis of col11a1 and TWiST1 protein expression in 30 colon cancer tissue samples. (c) Statistical analysis of 
col11a1 and TWiST1 protein levels in two different colon cancer clinical samples. col11a1 and TWiST1 were determined to be upregulated in right-sided 
tumors than in left-sided tumors. (d) Positive correlation between the expression of col11a1 and the expression of TWiST1 protein in two colon cancer 
clinical samples. results are representative of three independent experiments, and the error bars represent the standard deviation. col11a1, collagen type Xi 
α1 chain; TWiST1, Twist family bHlH transcription factor 1.
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associated with chemosensitivity to oxaliplatin and 5‑fluoro-
uracil (78). downregulation of TWiST1 expression induced 
apoptosis and enhanced the sensitivity of chemotherapy (78). 
Generally, TWiST1 can promote the chemotherapeutic resis-
tance of cancer cells (23), increase the number of cScs (74), 
as well as enhance aggression and metastasis of cancer 
cells (77,79-85) by suppressing their senescence and apop-
tosis induced by oncogenes. a study suggested that TWiST1 
may be used as a vital clinical biomarker for antiangiogenic 
therapy as its polymorphisms were related to the survival of 
patients with metastatic colorectal cancer who were treated 
with first-line bevacizumab-based chemotherapy (28). 
The present study proposed the importance of TWiST1 
upregulation in right-sided colonic cancer tissues. Patients 
with right-sided colonic cancer exhibited better outcomes 
of bevacizumab treatment than those with left-sided colon 
cancer (86).
Through our results, we also speculated that TWiST1 
may associated with col11a1 to enhance the develop-
ment of colon cancer. a study showed that the level of 
TWiST1 mrna had a positive correlation with that of 
col11a1 messenger rna in ovarian cancers. in addition, 
col11a1 could promote the activation of nuclear factor-κB 
by activating the transcription of iKKβ, and promote the 
expression of TWiST1, thereby regulating chemoresistance 
and apoptosis (44). in our experiments, we also demonstrated 
that TWiST1 could promote the progression of eMT, with 
the downregulation of e-cadherin and the upregulation of 
n-cadherin, while col11a may promote the transcrip-
tion of iKKβ in colon cancer cell (Fig. S1). This suggested 
the complexity of the regulatory mechanism mediated by 
these two proteins in left and right-sided colonic cancer. the 
limitations of our study include the small cohort of patients 
enrolled for analysis. 
in brief, our work suggested that the expression levels of 
col11a1 and TWiST1 differ between these two types colonic 
cancers and may be promising therapeutic targets for treating 
right-sided colonic cancer. However, further study is also 
necessary to illustrate the potential molecular mechanisms, 
and functions of col11a1 and TWiST1 between these two 
types of colonic cancer.
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